Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity.
URL: http://www.news-medical.net/news/20130107/Rhythm-commences-RM-493-Phase-2-trial-in-obesity.aspx
No comments:
Post a Comment